TrialClinical and translational gastroenterology2019
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
R K Kelley et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
166 papers cite itlatest 60 shown
this paperpooled ittrialcites it